Eslicar400 mg

Eslicar is an antiepileptic medicine (anticonvulsant) indicated for the treatment of partial-onset (focal) seizures. Its evidence-based uses include:

• Adjunctive therapy: approved and guideline-supported for use in combination with other antiepileptic drugs in adults and pediatric patients (per approved age range, generally 4 years and older) with partial-onset seizures.
• Monotherapy: approved for use as a single agent in adults with partial-onset seizures, either as initial treatment or after conversion from another antiepileptic drug.

Eslicar is not approved for generalized seizure types (e.g., absence seizures), and any use outside epilepsy management would be considered off-label and is not supported by strong evidence.

Each tablet of Eslicarbazepine Acetate contains eslicarbazepine acetate as the active ingredient, available in strengths such as 200 mg, 400 mg, 600 mg, and 800 mg (exact strengths marketed may vary by manufacturer). Eslicarbazepine Acetate is a dibenzazepine carboxamide derivative that is rapidly and extensively converted to its active metabolite, eslicarbazepine, after oral administration.

Eslicar is a third-generation antiepileptic drug belonging to the dibenzazepine carboxamide family, chemically related to carbamazepine and oxcarbazepine. It is administered orally as a prodrug and is converted almost entirely to its active form, eslicarbazepine, via first-pass hydrolysis. Eslicar is used for long-term management of partial-onset seizures in patients with epilepsy, either alone or together with other antiseizure medicines.

Eslicar belongs to the therapeutic class of antiepileptic drugs (anticonvulsants), specifically the dibenzazepine carboxamide derivatives, a class that also includes carbamazepine and oxcarbazepine.

Eslicarbazepine Acetate is rapidly hydrolyzed to its major active metabolite, eslicarbazepine, which is believed to exert its anticonvulsant effect primarily by blocking voltage-gated sodium channels in neurons. By stabilizing the inactivated state of these channels, Eslicarbazepine Acetate prevents their return to the activated state, thereby reducing repetitive neuronal firing and limiting the spread of seizure activity.

Following oral administration, eslicarbazepine reaches peak plasma concentration within 1-4 hours, with an elimination half-life of approximately 13-20 hours, allowing once-daily dosing. It undergoes limited hepatic metabolism (mainly glucuronidation) and is primarily excreted renally, largely unchanged, which is why dose adjustment is required in renal impairment.

Eslicar is taken orally, once daily, with or without food. Tablets should be swallowed whole with water and not crushed or chewed unless directed by a physician. It is best to take Eslicar at the same time each day to maintain consistent blood levels and seizure control.

Eslicar has several clinically significant drug interactions:

• Carbamazepine: concurrent use may decrease plasma levels of eslicarbazepine (increased clearance) and may increase the risk of adverse effects due to shared active-metabolite pathways; dose adjustment of Eslicar may be needed.
• Phenytoin: Eslicar may increase phenytoin plasma levels (via CYP2C19 inhibition), while phenytoin may decrease eslicarbazepine levels (enzyme induction); phenytoin dose reduction may be required.
• Hormonal contraceptives: Eslicar is a moderate inducer of CYP3A4 and may reduce the effectiveness of hormonal contraceptives; alternative or additional contraceptive methods are recommended during treatment.
• Warfarin: Eslicar may decrease plasma levels of warfarin, reducing anticoagulant effect; monitoring of INR is recommended when starting or stopping therapy.
• Other strong CYP3A4 inducers (e.g., rifampicin): may reduce plasma concentrations of eslicarbazepine, potentially reducing the efficacy of Eslicar.

Common side effects of Eslicar include:

• Dizziness
• Somnolence (drowsiness)
• Headache
• Nausea and vomiting
• Diplopia (double vision) and blurred vision
• Vertigo and disturbance in gait/coordination (ataxia)
• Fatigue and tremor

Less common but serious effects of Eslicar can include hyponatremia, severe skin reactions, and mood/behavioral changes; see Precautions and Warnings for details.

Eslicar, like other antiepileptic drugs, carries a potential risk of fetal harm, including congenital malformations, based on data from related drugs in this class. Eslicar should be used during pregnancy only if clearly needed and if the potential benefit to the mother justifies the potential risk to the fetus; abrupt discontinuation should be avoided, as uncontrolled seizures pose risks to both mother and fetus. Patients should consult their physician before and during pregnancy for individualized guidance.

It is not established with certainty whether Eslicar passes into human breast milk in clinically significant amounts; caution is advised, and a physician should be consulted to weigh the benefits of breastfeeding against potential risk to the infant.

• Suicidal thoughts/behavior: antiepileptic drugs, including Eslicar, may increase the risk of suicidal ideation or behavior; monitor for mood changes.
• Hyponatremia: Eslicar may cause clinically significant low sodium levels; monitor patients with symptoms such as confusion, nausea, or worsening seizures, especially those on other sodium-lowering medicines.
• Hypersensitivity/serious skin reactions: rash, angioedema, anaphylaxis, and severe cutaneous reactions (including DRESS and Stevens-Johnson syndrome) have been reported; discontinue Eslicar immediately if these occur.
• Cardiac conduction effects: Eslicar may shorten the QT interval; use caution in patients with familial short QT syndrome.
• CNS effects: Eslicar may impair mental/physical abilities (dizziness, somnolence); use caution with driving or operating machinery.
• Withdrawal seizures: do not stop Eslicar abruptly; discontinue gradually under physician supervision.
• Renal/hepatic impairment: requires dose adjustment or caution; see Use in Special Populations.

Overdose of Eslicar may cause dizziness, drowsiness, gastrointestinal disturbances, ataxia, and cardiac conduction abnormalities. If an overdose of Eslicar is suspected, seek immediate medical attention or contact emergency services/poison control right away. There is no specific antidote; treatment is supportive and may include monitoring of cardiac and neurological status.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Renal impairment

Dose reduction of Eslicar is recommended in patients with moderate to severe renal impairment (creatinine clearance below 50 mL/min); use is generally avoided in severe renal impairment or end-stage renal disease unless specifically directed by a physician.

Hepatic impairment

No dose adjustment is generally needed with mild to moderate hepatic impairment; Eslicar has not been studied in severe hepatic impairment and is not recommended in this population.

Elderly

Eslicar should be used with caution in elderly patients, with dose selection guided by renal function and concomitant conditions.

Pediatric

See Pediatric Uses section.

Treatment with Eslicar for epilepsy is typically long-term and individualized based on seizure control, tolerability, and physician assessment. It should not be stopped abruptly; any change in duration or discontinuation of Eslicar should be guided and gradually tapered by the treating physician.

Eslicarbazepine Acetate is classified as an antiepileptic drug (anticonvulsant); specifically a dibenzazepine carboxamide derivative and voltage-gated sodium channel blocker.

Eslicarbazepine Acetate is rapidly converted to eslicarbazepine, which blocks voltage-gated sodium channels by stabilizing their inactivated state. This action reduces sustained repetitive neuronal firing, thereby limiting the spread of abnormal electrical activity that underlies seizures.

C

Eslicar is approved for use as adjunctive therapy in pediatric patients typically 4 years of age and older with partial-onset seizures, with weight-based, individualized dosing under specialist supervision. Safety and efficacy of Eslicar have not been established in children below the approved age range. Close monitoring for growth, cognitive, and behavioral effects is recommended during long-term pediatric use.